Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Current Treatment Options in Oncology
Published in:

13-11-2024 | Cervical Cancer

Contemporary Review of Adenocarcinoma of the Cervix

Authors: N Desravines, C Tran, S Wethington, MY Williams-Brown

Published in: Current Treatment Options in Oncology | Issue 12/2024

Login to get access

Opinion Statement

Among cervical cancers, adenocarcinoma is less common than squamous cell carcinoma of the cervix; however, the incidence of these cancers is rising. The incidence has changed largely due to a shift in risk factors as well as the evolution of the diagnosis and classification of adenocarcinoma. Adenocarcinoma of the cervix is composed of a diverse group of neoplasms that can be classified by various factors. In this review article, preinvasive disease, updated classifications of adenocarcinoma, and treatment options for cervical adenocarcinoma are discussed with a focus on current and future therapies. Advances in antibody–drug conjugates (ADC) and immunotherapy have increased the treatment options available for usual-type adenocarcinoma but there is still a lack of variety of treatment options for the remaining 25% of non-usual-type adenocarcinomas.
Literature
1.
Cohen CM, Wentzensen N, Castle PE, Schiffman M, Zuna R, Arend RC, et al. Racial and ethnic disparities in cervical cancer incidence, survival, and mortality by histologic subtype. J Clin Oncol. 2023;41:1059–68.PubMedCrossRef
2.
Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019;123:316–23.PubMedCrossRef
3.
Pan X, Yang W, Wen Z, Li F, Tong L, Tang W. Does adenocarcinoma have a worse prognosis than squamous cell carcinoma in patients with cervical cancer? A real-world study with a propensity score matching analysis. J Gynecol Oncol. 2020;31:e80.PubMedPubMedCentralCrossRef
4.
Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human papillomavirus-negative cervical cancer: a comprehensive review. Front Oncol. 2020;10:606335.PubMedCrossRef
5.
Park KJ. Cervical adenocarcinoma: integration of HPV status, pattern of invasion, morphology and molecular markers into classification. Histopathology. 2020;76:112–27.
6.
Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States–a 24-year population-based study. Gynecol Oncol. 2000;78:97–105.PubMedCrossRef
7.
Park JJ, Sun D, Quade BJ, Flynn C, Sheets EE, Yang A, et al. Stratified mucin-producing intraepithelial lesions of the cervix: adenosquamous or columnar cell neoplasia? Am J Surg Pathol. 2000;24:1414–9.PubMedCrossRef
8.
Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:102–31.PubMedPubMedCentralCrossRef
9.
Teoh D, Musa F, Salani R, Huh W, Jimenez E. Diagnosis and management of adenocarcinoma in situ: a society of gynecologic oncology evidence-based review and recommendations. Obstet Gynecol. 2020;135:869–78.PubMedPubMedCentralCrossRef
10.
Wolf JK, Levenback C, Malpica A, Morris M, Burke T, Mitchell MF. Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. Obstet Gynecol. 1996;88:82–6.PubMedCrossRef
11.
Bhatla N, Berek JS, Cuello Fredes M, Denny LA, Grenman S, Karunaratne K, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019;145:129–35.PubMedCrossRef
12.
Wilbur D, Colgan T, Ferenczy A, Hirschowitz L, Loening T, McCluggage W. Glandular tumors and precursors. WHO classification of tumours of female reproductive organs Lyon. International Agency for Research on Cancer; 2014; 183–9.
13.
Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol. 2018;42:214–26.PubMedPubMedCentralCrossRef
14.
Stolnicu S, Hoang L, Chiu D, Hanko-Bauer O, Terinte C, Pesci A, et al. Clinical outcomes of HPV-associated and unassociated endocervical adenocarcinomas categorized by the International Endocervical Adenocarcinoma Criteria and Classification (IECC). Am J Surg Pathol. 2019;43:466–74.PubMedPubMedCentralCrossRef
15.
McCluggage WG, Singh N, Gilks CB. Key changes to the World Health Organization (WHO) classification of female genital tumours introduced in the 5th edition (2020). Histopathology. 2022;80:762–78.
16.
Hodgson A, Olkhov-Mitsel E, Howitt BE, Nucci MR, Parra-Herran C. International endocervical adenocarcinoma criteria and classification (IECC): correlation with adverse clinicopathological features and patient outcome. J Clin Pathol. 2019;72:347–53.PubMedCrossRef
17.
Nishio S, Mikami Y, Tokunaga H, Yaegashi N, Satoh T, Saito M, et al. Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: a multi-institutional study. Gynecol Oncol. 2019;153:13–9.PubMedCrossRef
18.
Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007;31:664–72.PubMedCrossRef
19.
Pirog EC, Park KJ, Kiyokawa T, Zhang X, Chen W, Jenkins D, et al. Gastric-type adenocarcinoma of the cervix: tumor with wide range of histologic appearances. Adv Anat Pathol. 2019;26:1–12.PubMedCrossRef
20.
Giannella L, Di Giuseppe J, Delli Carpini G, Grelloni C, Fichera M, Sartini G, et al. HPV-negative adenocarcinomas of the uterine cervix: from molecular characterization to clinical implications. Int J Mol Sci. 2022;23.
21.
Thomas MB, Wright JD, Leiser AL, Chi DS, Mutch DG, Podratz KC, et al. Clear cell carcinoma of the cervix: a multi-institutional review in the post-DES era. Gynecol Oncol. 2008;109:335–9.PubMedPubMedCentralCrossRef
22.
Liu Y, Shi X, Yang J, Zhou H, Peng P, Cao D. Clinical features and prognostic factors of cervical clear cell adenocarcinoma: a retrospective analysis of 74 cases from a tertiary hospital. Technol Cancer Res Treat. 2023;22:15330338221149296.PubMedPubMedCentralCrossRef
23.
Talia KL, Oliva E, Rabban JT, Singh N, Stolnicu S, McCluggage WG. Grading of endocervical adenocarcinomas: review of the literature and recommendations from the international society of gynecological pathologists. Int J Gynecol Pathol. 2021;40:S66–74.PubMedPubMedCentralCrossRef
24.
Alvarado-Cabrero I, Parra-Herran C, Stolnicu S, Roma A, Oliva E, Malpica A. The silva pattern-based classification for hpv-associated invasive endocervical adenocarcinoma and the distinction between in situ and invasive adenocarcinoma: relevant issues and recommendations from the international society of gynecological pathologists. Int J Gynecol Pathol. 2021;40:S48-s65.
25.
Rutgers JK, Roma AA, Park KJ, Zaino RJ, Johnson A, Alvarado I, et al. Pattern classification of endocervical adenocarcinoma: reproducibility and review of criteria. Mod Pathol. 2016;29:1083–94.PubMedPubMedCentralCrossRef
26.
Diaz De Vivar A, Roma AA, Park KJ, Alvarado-Cabrero I, Rasty G, Chanona-Vilchis JG, et al. Invasive endocervical adenocarcinoma: proposal for a new pattern-based classification system with significant clinical implications: a multi-institutional study. Int J Gynecol Pathol. 2013;32:592–601.PubMedCrossRef
27.
Obermair A, Asher R, Pareja R, Frumovitz M, Lopez A, Moretti-Marques R, et al. Incidence of adverse events in minimally invasive vs open radical hysterectomy in early cervical cancer: results of a randomized controlled trial. Am J Obstet Gynecol. 2020;222(249):e1–10.
28.
Paquette C, Jeffus SK, Quick CM, Conaway MR, Stoler MH, Atkins KA. Interobserver variability in the application of a proposed histologic subclassification of endocervical adenocarcinoma. Am J Surg Pathol. 2015;39:93–100.PubMedCrossRef
29.
Parra-Herran C, Taljaard M, Djordjevic B, Reyes MC, Schwartz L, Schoolmeester JK, et al. Pattern-based classification of invasive endocervical adenocarcinoma, depth of invasion measurement and distinction from adenocarcinoma in situ: interobserver variation among gynecologic pathologists. Mod Pathol. 2016;29:879–92.PubMedCrossRef
30.
National Comprehensive Cancer Network. Cervical Cancer (Version 1.2024).
31.
Frumovitz M, Sun CC, Schmeler KM, Deavers MT, Dos Reis R, Levenback CF, et al. Parametrial involvement in radical hysterectomy specimens for women with early-stage cervical cancer. Obstet Gynecol. 2009;114:93–9.PubMedCrossRef
32.
Schmeler KM, Pareja R, Lopez Blanco A, Humberto Fregnani J, Lopes A, Perrotta M, et al. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer. Int J Gynecol Cancer. 2021;31:1317–25.PubMedCrossRef
33.
National Comprehensive Cancer Network. Cervical Cancer (Version 3.2024).
34.
Plante M, Kwon JS, Ferguson S, Samouelian V, Ferron G, Maulard A, et al. Simple versus radical hysterectomy in women with low-risk cervical cancer. N Engl J Med. 2024;390:819–29.
35.
Sutton GP, Bundy BN, Delgado G, Sevin BU, Creasman WT, Major FJ, et al. Ovarian metastases in stage IB carcinoma of the cervix: a gynecologic oncology group study. Am J Obstet Gynecol. 1992;166:50–3.PubMedCrossRef
36.
Chen J, Wang R, Zhang B, Lin X, Wei J, Jia Y, et al. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis. Am J Obstet Gynecol. 2016;215(460):e1–13.
37.
Shimada M, Kigawa J, Nishimura R, Yamaguchi S, Kuzuya K, Nakanishi T, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecol Oncol. 2006;101:234–7.PubMedCrossRef
38.
Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med. 2018;379:1895–904.PubMedCrossRef
39.
Melamed A, Margul DJ, Chen L, Keating NL, Del Carmen MG, Yang J, et al. Survival after minimally invasive radical hysterectomy for early-stage cervical cancer. N Engl J Med. 2018;379:1905–14.PubMedPubMedCentralCrossRef
40.
Grigsby PW, Massad LS, Mutch DG, Powell MA, Thaker PH, McCourt C, et al. FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival. Gynecol Oncol. 2020;157:639–43.PubMedCrossRef
41.
Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73:177–83.PubMedCrossRef
42.
Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 2006;65:169–76.PubMedCrossRef
43.
Levinson K, Beavis AL, Purdy C, Rositch AF, Viswanathan A, Wolfson AH, et al. Beyond sedlis-a novel histology-specific nomogram for predicting cervical cancer recurrence risk: an NRG/GOG ancillary analysis. Gynecol Oncol. 2021;162:532–8.PubMedPubMedCentralCrossRef
44.
Feng Y, Zhang Z, Lou T, Wang S, Bai H, Zhang Z. The safety of fertility preservation for microinvasive cervical adenocarcinoma: a meta-analysis and trial sequential analysis. Arch Gynecol Obstet. 2018;298:465–75.PubMedCrossRef
45.
Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, et al. The european society of gynaecological oncology/european society for radiotherapy and oncology/european society of pathology guidelines for the management of patients with cervical cancer. Int J Gynecol Cancer. 2018;28:641–55.PubMedCrossRef
46.
Abu-Rustum NR, Neubauer N, Sonoda Y, Park KJ, Gemignani M, Alektiar KM, et al. Surgical and pathologic outcomes of fertility-sparing radical abdominal trachelectomy for FIGO stage IB1 cervical cancer. Gynecol Oncol. 2008;111:261–4.PubMedPubMedCentralCrossRef
47.
Cibula D, Slama J, Svarovsky J, Fischerova D, Freitag P, Zikan M, et al. Abdominal radical trachelectomy in fertility-sparing treatment of early-stage cervical cancer. Int J Gynecol Cancer. 2009;19:1407–11.PubMedCrossRef
48.
Karateke A, Kabaca C. Radical abdominal trachelectomy is a safe and fertility preserving option for women with early stage cervical cancer. Eur J Gynaecol Oncol. 2012;33:200–3.PubMed
49.
Wethington SL, Sonoda Y, Park KJ, Alektiar KM, Tew WP, Chi DS, et al. Expanding the indications for radical trachelectomy: a report on 29 patients with stage IB1 tumors measuring 2 to 4 centimeters. Int J Gynecol Cancer. 2013;23:1092–8.PubMedPubMedCentralCrossRef
50.
Girda E, Randall LM, Chino F, Monk BJ, Farley JH, O’Cearbhaill RE. Cervical cancer treatment update: a society of gynecologic oncology clinical practice statement. Gynecol Oncol. 2023;179:115–22.PubMedPubMedCentralCrossRef
51.
Eifel PJ, Moughan J, Erickson B, Iarocci T, Grant D, Owen J. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. Int J Radiat Oncol Biol Phys. 2004;60:1144–53.PubMedCrossRef
52.
Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154–61.PubMedCrossRef
53.
Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606–13.PubMedCrossRef
54.
Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 1999;17:2676–80.PubMedCrossRef
55.
Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study. J Clin Oncol. 1999;17:1339–48.PubMedCrossRef
56.
Mileshkin LR, Moore KN, Barnes EH, Gebski V, Narayan K, King MT, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:468–82.PubMedPubMedCentralCrossRef
57.
Monk BJ, Toita T, Wu X, Vázquez Limón JC, Tarnawski R, Mandai M, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24:1334–48.PubMedCrossRef
58.
Lorusso D, Xiang Y, Hasegawa K, Scambia G, Leiva M, Ramos-Elias P, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403:1341–50.
59.
Garcia-Duran C, Grau F, Villacampa G, Oaknin A. ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation. Int J Gynecol Cancer. 2022.
60.
Gustave Roussy CCGP. Trial Assessing the inhibitor of programmed cell death ligand 1 (PD-L1) immune checkpoint Atezolizumab. 2024.
61.
Mayadev JS. Atezolizumab before and/or with chemoradiotherapy in immune system activation in patients with node positive Stage IB2, II, IIIB, or IVA cervical cancer. 2024.
62.
Bugano D. Atezolizumab before and/or with chemoradiotherapy in immune system activation in patients with node positive stage IB2, II, IIIB, or IVA cervical cancer. 2024.
63.
McCormack M, Gallardo Rincón D, Eminowicz G, Diez P, Farrelly L, Kent C, et al. LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial. Ann Oncol. 2023;34:S1276.CrossRef
64.
Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113–9.PubMedCrossRef
65.
Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol. 2009;27:4649–55.PubMedPubMedCentralCrossRef
66.
Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734–43.PubMedPubMedCentralCrossRef
67.
Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385:1856–67.PubMedCrossRef
68.
Song F, Jia M, Yu S, Cao L, Sun PL, Gao H. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma. Histopathology. 2021;79:861–71.PubMedCrossRef
69.
Vergote I, Gonzalez-Martin A, Fujiwara K, Kalbacher E, Bagameri A, Ghamande S, et al. Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med. 2024;391:44–55.
70.
Vergote I, Van Nieuwenhuysen E, O’Cearbhaill RE, Westermann A, Lorusso D, Ghamande S, et al. Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study. J Clin Oncol. 2023;41:5536–49.PubMedPubMedCentralCrossRef
71.
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, Gonzalez-Martin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 Phase II trial. J Clin Oncol. 2024;42:47–58.PubMedCrossRef
72.
Itkin B, Garcia A, Straminsky S, Adelchanow ED, Pereyra M, Haab GA, et al. Prevalence of HER2 overexpression and amplification in cervical cancer: a systematic review and meta-analysis. PLoS ONE. 2021;16:e0257976.PubMedPubMedCentralCrossRef
73.
Shi H, Shao Y, Lu W, Lu B. An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the international endocervical adenocarcinoma criteria and classification. J Pathol Clin Res. 2021;7:86–95.PubMedCrossRef
74.
Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, et al. Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol. 2015;39:1449–57.PubMedPubMedCentralCrossRef
75.
Ehmann S, Sassine D, Straubhar AM, Praiss AM, Aghajanian C, Alektiar KM, et al. Gastric-type adenocarcinoma of the cervix: clinical outcomes and genomic drivers. Gynecol Oncol. 2022;167:458–66.PubMedPubMedCentralCrossRef
76.
77.
Kido A, Mikami Y, Koyama T, Kataoka M, Shitano F, Konishi I, et al. Magnetic resonance appearance of gastric-type adenocarcinoma of the uterine cervix in comparison with that of usual-type endocervical adenocarcinoma: a pitfall of newly described unusual subtype of endocervical adenocarcinoma. Int J Gynecol Cancer. 2014;24:1474–9.PubMedCrossRef
78.
Kojima A, Shimada M, Mikami Y, Nagao S, Takeshima N, Sugiyama T, et al. Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the sankai gynecology study group. Int J Gynecol Cancer. 2018;28:99–106.PubMedCrossRef
79.
Ueno S, Sudo T, Oka N, Wakahashi S, Yamaguchi S, Fujiwara K, et al. Absence of human papillomavirus infection and activation of PI3K-AKT pathway in cervical clear cell carcinoma. Int J Gynecol Cancer. 2013;23:1084–91.PubMedCrossRef
80.
Combination of PD-1 monoclonal antibody and HPV vaccine in patients with cervical cancer.
81.
Study of SQZ-PBMC-HPV in patients with HPV16+ recurrent, locally advanced or metastatic solid tumors.
82.
Pharmaceuticals ISA, Dutch Cancer S. Study of the therapeutic vaccine (ISA101/ISA101b) to treat advanced or recurrent cervical cancer. 2018.
83.
University of S, Bio NSE. HARE-40: HPV Anti-CD40 RNA vaccinE. 2023.
84.
Sidney Kimmel Comprehensive Cancer Center at Johns H, National Cancer I, PapiVax Biotech I. Safety and feasibility of TA-CIN vaccine in HPV16 associated cervical cancer. 2024.
85.
Transgene, Merck KgaA DG, Research EMDS, Development Institute I, Pfizer. Phase Ib/II of TG4001 and avelumab in HPV16 Positive R/M cancers. 2023.
86.
European Organisation for R, Treatment of Cancer E. Surgery and vaccine therapy in treating patients with early cervical cancer.
87.
Look KY, Blessing JA, Michener CM, Rubin S, Ramirez PT. Phase II evaluation of capecitabine in refractory nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2008;18:773–8.PubMedCrossRef
88.
Università Politecnica delle M. Adenocarcinoma of the uterine cervix and HPV. 2023.
89.
Center MDAC. Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix. 2023.
90.
Center MDAC. Establishing a tumor registry for patients with neuroendocrine carcinoma of the cervix. 2044.
91.
Shanghai Jiatan Pharmatech Co L. A study of WX390 combined with toripalimab in patients with advanced gastric-type endocervical adenocarcinoma with STK11 mutations. 2025.
92.
Center MDAC. Phase II study of AK104 (Cadonilimab) for recurrent small cell neuroendocrine carcinomas of the cervix. 2025.
93.
Nishio H, Matsuda R, Iwata T, Yamagami W. Gastric-type adenocarcinoma of the uterine cervix: clinical features and future directions. Jpn J Clin Oncol. 2024.
94.
Praiss AM, White C, Iasonos A, Selenica P, Zivanovic O, Chi DS, et al. Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: a single-center experience with molecular characterization, treatment, and oncologic outcomes. Gynecol Oncol. 2024;182:32–8.PubMedCrossRef
Metadata
Title
Contemporary Review of Adenocarcinoma of the Cervix
Authors
N Desravines
C Tran
S Wethington
MY Williams-Brown
Publication date
13-11-2024
Publisher
Springer US
Published in
Current Treatment Options in Oncology / Issue 12/2024
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI
https://doi.org/10.1007/s11864-024-01254-9

Other articles of this Issue 12/2024

Advances in Understanding Drug Resistance Mechanisms and Innovative Clinical Treatments for Melanoma

Treatment Options for IDH-Mutant Malignant Gliomas

Molecular Secrets Revealed: How Diabetes may be Paving the Way for Leukemia

Oligometastatic Breast Cancer: Seeking the Cure by Redefining Stage IV Disease?

Updates in Treatment of HER2-positive Metastatic Breast Cancer

New Therapeutic Targets in RAS Wild-type Pancreatic Cancer

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Video
Image Credits